Q3 2022 Results
Company overview
Financial review
2022 priorities
Financial performance
Innovation: Pipeline overview
Cardiovascular
Immunology
Neuroscience
Ophthalmology
Global Health
ganaplacide - Imidazolopiperazines derivative
NCT04546633 KALUMI (CKAF156A2203)
Indication
Phase
Malaria, uncomplicated
Phase 2
PCR-corrected and uncorrected Adequate Clinical and Parasitological
Response (ACPR)
Patients
292
Primary
Outcome
Measures
Arms
Intervention
KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition
KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition
Malaria patients 6 months to < 18 years old
Target
Patients
Read-out
Milestone(s)
2023
Publication
TBD
Appendix
Innovation: Clinical trials
References
Abbreviations
Oncology
Other
Biosimilars
91 Investor Relations | Q3 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation